🔗 Share this article

Given that the US continues making historic revisions to its immunization recommendations, one figure appears somewhat surprisingly: Dr. Tracy Beth Høeg, an American of Danish descent sports medicine doctor and epidemiologist who initially gained attention by questioning coronavirus vaccinations in the global health crisis and has concentrated on possible deaths after Covid immunization in her recent tenure at the Food and Drug Administration.

Proposed Changes to Childhood Immunization Program

Health officials were set to announce major revisions to the pediatric vaccine schedule earlier this month, bringing the US with the Danish immunization schedule, according to reports – a major change that would put the US out of step with a large portion of the international standard with no evidence for public health gain. This reveal has been pushed back until the next year.

Rather than Vinay Prasad, Høeg is listed to speak at the event. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to lead the center this calendar year.

A New Direction at the FDA

This interim role might represent a strengthened alliance between the drug and vaccine divisions as Dr. Høeg and Dr. Prasad strengthen their influence at the FDA – and it points to a greater focus upon dismantling previously authorized immunizations at the FDA.

The new acting director has frequently advocated for halting some pediatric immunization guidelines in the US in order to be more similar to Denmark's approach, a society with comprehensive healthcare and a population roughly the size of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on immunizations – usually the domain of Prasad, head of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Background

Høeg has no apparent background in pharmaceutical research, oversight or leadership, which has been customary for past leaders of the CBER. She has been employed at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for leading the drug-regulation department, remarked Dr. Jonathan Howard. “She lacks experience running a scientific study. She lacks experience in leading a sizeable institution. She lacks background in pharmaceutical oversight.”

Previous heads of the center would “grasp legal statutes and the science of drug development”, said a former acting FDA commissioner. “Clearly, she doesn’t have the type of experience that previous people who led CBER have had.”

CDER has an enormous portfolio at the FDA, she stated.

“Many people just zeroes in on the new drug program, but the generic drug division clears numerous generic drugs. There’s a biologic copycat branch, non-prescription drug unit and so forth, and every single one need to be looked after,” she explained. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Furthermore, a major leadership element to the role, which oversees in excess of 5,000 personnel. “It is a enormous administrative position, if you execute it properly,” Woodcock added.

Agency Reaction and Disputed Initiatives

When asked about concerns about Høeg’s qualifications and whether this appointment signifies increased cooperation among FDA leaders on vaccines, a spokesperson responded that the “concerns rely on inaccurate assumptions”.

“Her resume aligns with the responsibilities of her position,” the official stated, pointing to the months Dr. Høeg spent advising the agency head on “medication safety and regulatory science, including predictive safety algorithms and immunization monitoring”.

As the temporary head, Høeg takes over the commissioner’s controversial fast-track approval initiative, a disputed rapid drug-approval program that allegedly worried her former heads. “By what process are these therapies being chosen for this expedited pathway? Who makes the decisions?” Dr. Howard said. “There is a lot of secrecy going on at the agency right now.”

In general, he said, “the agency appears to be shifting towards less stringent rules of pharmaceuticals, aside from vaccines.”

Public Past Work on Vaccines

Concerning immunizations, Høeg has a clearer, if troubling, track record, Howard have noted. She authored a research paper using unverified volunteer-provided data to estimate the incidence of myocarditis after COVID-19 vaccination. She advised the Florida chief medical officer Dr. Joseph Ladapo, who allegedly have modified findings to indicate Covid vaccines are pose a greater threat than they are.

Among her “desired changes” for the new government encompassed altering guidelines for new vaccines and discontinuing “optional” immunizations, she said post-election on a online show. At the agency, Dr. Høeg has reportedly suggested excluding teenage boys from getting Covid vaccines.

“She’s an thorough ideologue who begins with her beliefs and works backwards to fit the science in a highly misleading, fraudulent manner,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Høeg joined fellow skeptics, {like|